Preliminary Results of a Phase II Study of Surufatinib Plus Sintilimab, Nab-Paclitaxel and Gemcitabine (AG) As First-Line Therapy in Patients (pts) with Locally Advanced or Metastatic Pancreatic Adenocarcinoma (Mpdac).